First Tracks Biotherapeutics
- Company typePublic
- Founded2026
- HeadquartersSan Diego, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
First Tracks Biotherapeutics firmographics
Firmographics- Name
- First Tracks Biotherapeutics
- Legal name
- First Tracks Biotherapeutics, Inc.
- Website
- https://firsttracksbio.com
- Company type
- Public
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
First Tracks Biotherapeutics industry classification
Industry- Product category
- Antibody Therapeutics
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA)
- akta.pro secondary industries
- Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB), Immunology & Inflammation Pharmaceuticals (HLAIAAAD), Rare Immunology, Autoimmune & Autoinflammatory Therapies (HLAIAIAE)
Keywords
Where First Tracks Biotherapeutics is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
First Tracks Biotherapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Product Revenue: Pre-revenue clinical-stage company with no commercialized products. Future revenue dependent on successful clinical development and commercialization of pipeline assets ANB033, rosnilimab, and ANB101.
- Private Placement Funding: Company secured $145 million in private placement commitments prior to spin-off, with $80 million in gross proceeds going directly to the company at $13.81 per share. Represents capital financing, not operational revenue.
Go-to-market motion2 records
Marketing channels4 records
First Tracks Biotherapeutics product offering
Product offeringCore offering
First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. The company's pipeline consists of three development-stage assets: ANB033 (anti-CD122 antagonist in Phase 1b for celiac disease and eosinophilic esophagitis), Rosnilimab (anti-PD-1 antibody with completed Phase 2b for rheumatoid arthritis), and ANB101 (BDCA2-modulating antibody in Phase 1a). The company targets upstream immune pathways to selectively modulate pathogenic immune cells while preserving immune homeostasis.
Product overview
First Tracks Biotherapeutics is a clinical-stage biotechnology company advancing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. The portfolio consists of three development-stage assets: ANB033 (a novel anti-CD122 antagonist in Phase 1b for celiac disease and eosinophilic esophagitis), rosnilimab (a first-in-class pathogenic T-cell depleter with completed Phase 2b for rheumatoid arthritis), and ANB101 (a BDCA2-modulating antibody in Phase 1a). The company operates with deep research expertise in immunology, targeting activated immune cells in both the periphery and affected tissues to modulate critical pathways regulating autoimmunity and inflammation.
Differentiator
Problem solved
Functional benefit
Products and services
- ANB033 A novel anti-CD122 antagonist antibody that targets the shared beta subunit of the IL-15 and IL-2 receptors, offering a dual-pathway approach to reducing pathogenic inflammation. Currently in Phase 1b trials for celiac disease and eosinophilic esophagitis. The product modulates proliferation and survival of CD8+, CD4+ T cells, NK cells, and ILC2s.
- Rosnilimab A first-in-class anti-PD-1 antibody engineered to selectively deplete pathogenic T cells in both the periphery and inflamed tissues while sparing naive T cells. The product aims to restore immune homeostasis without broad immune suppression and is currently being studied in rheumatoid arthritis with completed Phase 2b trials showing JAK-like efficacy through 6 months with no treatment-related serious adverse events across approximately 185 patient-years of exposure.
- ANB101 A BDCA2-modulating antibody designed to specifically target plasmacytoid dendritic cells (pDCs), inhibiting interferon secretion and downstream immune activation. The product is more potent than litifilimab with longer half-life and deeper, more durable PD effect on pDC depletion. Currently in Phase 1a trials, it is positioned as an upstream modulator of immune activity across autoimmune and inflammatory diseases.
Quantifiable outcome
- ANB033 Phase 1b topline data expected Q4 2026 for celiac disease and mid-2027 for eosinophilic esophagitis
- +1 more outcomes
Companies that use First Tracks Biotherapeutics
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles4 records
First Tracks Biotherapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
First Tracks Biotherapeutics partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered supporting.
- Celiac Disease FoundationsupportingPatient advocacy partnership supporting celiac disease community through patient engagement initiatives, community walks, and collaboration on patient-centered drug development approach.
- Beyond CeliacsupportingPatient advocacy partnership working to elevate patient voices and strengthen connections that move meaningful therapies forward for celiac disease patients.
- Arthritis FoundationsupportingPartnership with patient advocacy organization supporting arthritis community, aligning with rosnilimab development for rheumatoid arthritis.
- National Rheumatoid Arthritis Society (NRAS)supportingUK-based patient organization partnership supporting rheumatoid arthritis patients and advocacy efforts.
- Association of European Coeliac Societies (AOECS)supportingEuropean patient advocacy partnership supporting celiac disease communities across Europe.
- American Partnership for Eosinophilic Disorders (APFED)supportingPatient advocacy partnership supporting patients with eosinophilic disorders, aligning with ANB033 development for eosinophilic esophagitis.
Scale indicators6 records
Recent moves9 records
Expansion highlights5 records
First Tracks Biotherapeutics competitors and assessment
Company assessmentDirect peers
- MoonLake Immunotherapeutics: Clinical-stage immunology biotech developing antibody therapeutics (e.g., sonelokimab targeting IL-17A/F/ALB) for autoimmune and inflammatory diseases including hidradenitis suppurativa and psoriatic arthritis. Most comparable to First Tracks Bio as a similarly-stage, similarly-sized biotech focused on inflammation biologics with differentiated antibody designs.
- Arcutis Biotherapeutics: Dermatology-focused biotech with approved and clinical-stage antibody/biologic therapies for inflammatory skin conditions (e.g., ZORYVE for psoriasis/atopic dermatitis). Comparable to First Tracks Bio as a clinical-stage inflammation biotech targeting chronic immune-mediated diseases with biologics.
- Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders for immunology and inflammation indications, including autoimmune diseases. Comparable to First Tracks Bio as a clinical-stage immunology-focused biotech with novel mechanisms and multiple pipeline programs aimed at autoimmune disease.
Others
- AnaptysBio: Former parent company of First Tracks Bio, now operating as a royalty-focused entity after spinning off its biopharma pipeline in April 2026. Included as a related-party peer given shared antibody discovery heritage and historical pipeline continuity.
Broad incumbents
- Eli Lilly: Global biopharma with multiple autoimmune/inflammation products including Olumiant (JAK inhibitor for RA) and Taltz (IL-17 inhibitor). Lilly's JAK franchise is the benchmark First Tracks' rosnilimab aims to compete with, making Lilly a key comparable incumbent.
- AbbVie: Global biopharma with leading autoimmune franchises including Skyrizi, Rinvoq, and Humira across RA, psoriasis, IBD, and other indications. Comparable to First Tracks Bio as the dominant incumbent in the autoimmune/inflammation therapeutic area that First Tracks' pipeline aims to compete with.
- Bristol-Myers Squibb: Major biopharma with autoimmune/inflammation assets including Zeposia and Sotyktu (deucravacitinib) for ulcerative colitis, psoriasis, and other indications. Comparable to First Tracks Bio as an incumbent in the autoimmune space with competing oral and biologic therapies.
- Incyte Corporation: Commercial-stage biopharma with multiple approved immunology products (e.g., Opzelura for atopic dermatitis, Jakafi) and a pipeline spanning autoimmune/inflammatory disease. Comparable to First Tracks Bio as a major developer of immunology therapeutics, though Incyte is at commercial scale.
Emerging players
- Alumis: Clinical-stage immunology biotech developing tyrosine kinase inhibitors for autoimmune diseases including psoriasis and lupus. Comparable to First Tracks Bio as a clinical-stage immunology company targeting autoimmune and inflammatory disease with novel mechanisms.
- Cabaletta Bio: Clinical-stage biotech developing cell therapies for autoimmune diseases such as pemphigus, SLE, and myositis. Comparable to First Tracks Bio as a clinical-stage company focused on modulating pathogenic immune responses in autoimmune indications.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
First Tracks Biotherapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
First Tracks Biotherapeutics leadership team
Management profileNumber of profiles
Profiles16 records
First Tracks Biotherapeutics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
First Tracks Biotherapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about First Tracks Biotherapeutics
What does First Tracks Biotherapeutics do?
First Tracks Biotherapeutics is a clinical-stage biotechnology company developing antibody therapeutics that modulate immune pathways implicated in autoimmune and inflammatory diseases. The company's pipeline consists of three development-stage assets: ANB033 (anti-CD122 antagonist in Phase 1b for celiac disease and eosinophilic esophagitis), Rosnilimab (anti-PD-1 antibody with completed Phase 2b for rheumatoid arthritis), and ANB101 (BDCA2-modulating antibody in Phase 1a). The company targets upstream immune pathways to selectively modulate pathogenic immune cells while preserving immune homeostasis.
Is First Tracks Biotherapeutics a public or private company?
First Tracks Biotherapeutics is a public company. It is classified as public and is currently operating.
When was First Tracks Biotherapeutics founded?
First Tracks Biotherapeutics was founded in 2026. It employs 51 to 100 people.
Where is First Tracks Biotherapeutics based?
First Tracks Biotherapeutics is headquartered in San Diego, United States, in the North America region.
How does First Tracks Biotherapeutics make money?
Two revenue lines are on record. Product Revenue is the primary driver. The others are private Placement Funding.
Who are First Tracks Biotherapeutics's main competitors?
Direct peers on record are MoonLake Immunotherapeutics, Arcutis Biotherapeutics and Kymera Therapeutics. AnaptysBio is listed as an others. Broad incumbents are Eli Lilly, AbbVie, Bristol-Myers Squibb and Incyte Corporation. Emerging players are Alumis and Cabaletta Bio.
Does First Tracks Biotherapeutics have an API?
No public API is recorded for First Tracks Biotherapeutics.
What industry is First Tracks Biotherapeutics in?
First Tracks Biotherapeutics's product category is Antibody Therapeutics. Its primary akta.pro industry code is HLAAAAAA, Monoclonal Antibody Therapeutics (mAbs), with a secondary code of HLAIACAB, Immunology & Autoimmune Specialty Pharmaceuticals. Its NAICS code is 325414 and its SIC code is 2836.